AGL 8.44 Increased By ▲ 0.14 (1.69%)
ANL 10.80 Increased By ▲ 0.21 (1.98%)
AVN 79.40 Increased By ▲ 0.80 (1.02%)
BOP 5.55 Increased By ▲ 0.10 (1.83%)
CNERGY 5.48 Decreased By ▼ -0.11 (-1.97%)
EFERT 80.00 Decreased By ▼ -0.25 (-0.31%)
EPCL 68.66 Decreased By ▼ -0.94 (-1.35%)
FCCL 15.00 Decreased By ▼ -0.30 (-1.96%)
FFL 6.49 Decreased By ▼ -0.04 (-0.61%)
FLYNG 7.27 Increased By ▲ 0.09 (1.25%)
GGGL 10.90 Increased By ▲ 0.05 (0.46%)
GGL 16.98 Increased By ▲ 0.19 (1.13%)
GTECH 8.18 Increased By ▲ 0.04 (0.49%)
HUMNL 7.11 Increased By ▲ 0.07 (0.99%)
KEL 3.07 Increased By ▲ 0.08 (2.68%)
LOTCHEM 32.65 Increased By ▲ 1.88 (6.11%)
MLCF 28.80 Decreased By ▼ -0.18 (-0.62%)
OGDC 84.70 Increased By ▲ 1.95 (2.36%)
PAEL 16.81 Decreased By ▼ -0.16 (-0.94%)
PIBTL 6.00 Decreased By ▼ -0.08 (-1.32%)
PRL 18.13 Increased By ▲ 0.03 (0.17%)
SILK 1.16 Increased By ▲ 0.01 (0.87%)
TELE 11.36 Increased By ▲ 0.11 (0.98%)
TPL 9.25 Increased By ▲ 0.05 (0.54%)
TPLP 20.07 Increased By ▲ 0.19 (0.96%)
TREET 26.55 Increased By ▲ 0.09 (0.34%)
TRG 96.99 Increased By ▲ 2.39 (2.53%)
UNITY 20.15 Increased By ▲ 0.65 (3.33%)
WAVES 13.88 Decreased By ▼ -0.46 (-3.21%)
WTL 1.33 Increased By ▲ 0.03 (2.31%)
BR100 4,247 Increased By 59.7 (1.43%)
BR30 15,625 Increased By 151.8 (0.98%)
KSE100 42,540 Increased By 443.3 (1.05%)
KSE30 16,108 Increased By 224.8 (1.42%)

WASHINGTON: Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.

Pfizer's CEO Albert Bourla previously said at a conference that the pharmaceutical giant could be ready to file for regulatory approval of the shot by March.

The company's head of vaccine research Kathrin Jansen said in a statement that while current data showed that boosters against the original Covid strain continued to protect against severe outcomes with Omicron, the company was acting out of caution.

"We recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," she said.

Ugur Sahin, CEO of the German biotech company BioNTech added that the protection of the original vaccine against mild and moderate Covid appeared to wane more rapidly against Omicron.

"This study is part of our science-based approach to develop a variant-based vaccine that achieves a similar level of protection against Omicron as it did with earlier variants but longer duration of protection."

The trial will involve 1,420 people aged 18-55.

A spokesperson for Pfizer told AFP that it did not include people older than 55 because the goal of the study was to examine the immune response of participants dosed, rather than estimate vaccine efficacy.

The volunteers are split into three groups.

EU regulator set to rule on Pfizer COVID pill by end-Jan, ahead of Merck

The first involves people who previously received two doses of the current Pfizer-BioNTech vaccine 90-180 days prior to enrollment, and will receive one or two doses of the Omicron vaccine.

The second will be people who got three doses of the current vaccine 90-180 days prior to the study and will receive either another dose of the original shot or an Omicron-specific vaccine.

The third and final group are people who have never previously received a Covid vaccine, and will receive three doses of the Omicron-specific vaccine.

The Pfizer-BioNTech vaccine was the first Covid shot to be authorized in the West, in December 2020.

Because it is based on messenger RNA technology, it is relatively easy to update to reflect the genetic code of new variants.

Several countries have begun to emerge from their latest waves driven by Omicron, the most transmissible strain to date, even though global new cases are still rising.

The coronavirus has killed some 5.6 million people since the outbreak emerged in China in December 2019.

Comments

Comments are closed.